- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05734105
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)
April 24, 2024 updated by: Deciphera Pharmaceuticals LLC
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations.
Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Team
- Phone Number: 785-830-2100
- Email: Clinicaltrials@deciphera.com
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Recruiting
- Alfred Health
-
-
-
-
-
Rio De Janeiro, Brazil, 20231
- Recruiting
- INCA - Instituto Nacional de Cancer
-
São Paulo, Brazil, 01509-900
- Recruiting
- AC Camargo Câncer Center
-
-
SP
-
São Paulo, SP, Brazil, 01409-002
- Recruiting
- Hospital 9 de Julho
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brazil, 88034-000
- Recruiting
- CEPEN - Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
-
Sao Paulo
-
Barretos, Sao Paulo, Brazil, 14748-400
- Recruiting
- Hospital de Cancer de Barretos - Fundacao Pio XII
-
São Paulo, Sao Paulo, Brazil, 01308
- Recruiting
- Hospital Sirio-Libanes
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Recruiting
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network, Princess Margaret Cancer Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Centre
-
-
-
-
RM
-
Las Condes, RM, Chile, 7620002
- Recruiting
- Clínica San Carlos De Apoquindo Red Salud UC Christus
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Palermo, Italy, 90127
- Recruiting
- U.O.C. Oncologia Medica
-
Roma, Italy, 00128
- Recruiting
- Università Campus Bio-Medico di Roma
-
-
Napoli
-
Naples, Napoli, Italy, 80131
- Recruiting
- Istituto Nazionale Tumori IRCCS Fondazione "G Pascale"
-
-
-
-
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
-
-
-
-
Groningen, Netherlands, 9713
- Recruiting
- UMC Groningen
-
Leiden, Netherlands, 2333 ZA
- Recruiting
- LUMC
-
-
-
-
Warszawa
-
Warsaw, Warszawa, Poland, 02-781
- Recruiting
- Narodowy Instytut Onkologii Im . Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spain, 08041
- Recruiting
- Hospital de la Santa Creu i Sant Pau
-
Valencia, Spain, 46009
- Recruiting
- Instituto Valenciano de Oncologia - IVO
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36312
- Recruiting
- Complejo Hospitalario Universitario de Vigo - Hospital Alvaro Cunqueiro
-
-
-
-
-
Taichung, Taiwan, 40447
- Recruiting
- China Medical University Hospital
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital
-
-
-
-
Greater London
-
London, Greater London, United Kingdom, SW3 6JJ
- Recruiting
- The Royal Marsden Hospital NHS Foundation Trust
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS9 7TF
- Recruiting
- St. James University Hospital
-
-
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- UC San Diego Moores Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale University
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic Florida
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- M Health Fairview University of Minnesota Medical Center
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 11042
- Recruiting
- Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Columbus, Ohio, United States, 43210
- Recruiting
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- OU Health Stephenson Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ≥18 years of age.
- Histologic diagnosis of GIST with co-occurring KIT exons 11+17/18 mutations confirmed by ctDNA sample.
- Participants must have advanced GIST and radiologic progression on imatinib treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2 at screening.
- Female participants of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug.
- Participants of reproductive potential must agree to follow contraception requirements.
- Participants must have at least 1 measurable lesion according to mRECIST v1.1 within 21 days prior to the first dose of study drug.
- Adequate organ function and bone marrow reserve based on laboratory assessments performed at screening.
- Resolution of all toxicities from prior therapy to Grade ≤1 (or participant baseline) within 1 week prior to the first dose of study drug.
Exclusion Criteria:
- History of KIT exon 9 mutation or detection of KIT exon 9, 13, or 14 mutations in a ctDNA sample.
- Has known active central nervous system metastases.
- New York Heart Association Class II-IV heart disease, myocardial infarction within 6 months of Cycle 1 Day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or congestive heart failure.
- Use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A prior to the first dose of study drug, and consumption of grapefruit or grapefruit juice within 14 days prior to the first dose of study drug.
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug.
- Known human immunodeficiency virus or hepatitis C infection only if the participant is taking medications that are excluded per protocol, acute or chronic hepatitis B, or acute or chronic hepatitis C infection.
Gastrointestinal abnormalities including, but not limited to:
- inability to take oral medication
- malabsorption syndromes
- requirement for intravenous alimentation
- Any active bleeding excluding hemorrhoidal or gum bleeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ripretinib
150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles.
|
50 mg tablets
Other Names:
|
Active Comparator: Sunitinib
50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles.
Sunitinib will be given continuously for 4 weeks with a 2-week break.
|
12.5 mg tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: Up to end of treatment; up to approximately 48 months
|
The time from randomization until documented progressive disease (PD) based on IRR per mRECIST or death due to any cause, whichever occurs first.
|
Up to end of treatment; up to approximately 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to end of treatment; up to approximately 48 months
|
Compare ORR by IRR of ripretinib vs sunitinib using mRECIST
|
Up to end of treatment; up to approximately 48 months
|
Overall Survival (OS)
Time Frame: Up to approximately 48 months
|
Compare OS of ripretinib vs sunitinib
|
Up to approximately 48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Team, Deciphera Pharmaceuticals LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2023
Primary Completion (Estimated)
February 1, 2026
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
February 8, 2023
First Submitted That Met QC Criteria
February 8, 2023
First Posted (Actual)
February 17, 2023
Study Record Updates
Last Update Posted (Actual)
April 25, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCC-2618-03-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GIST
-
Indiana UniversityCompleted
-
Novartis PharmaceuticalsActive, not recruitingGIST and CMLChina, Turkey, Singapore, France, Switzerland, Thailand, United States, Romania, Hong Kong, Finland, United Kingdom
-
Leiden University Medical CenterUnknown
-
European Organisation for Research and Treatment...Withdrawn
-
Peking UniversityUnknown
-
PfizerCompletedGISTUnited States, Switzerland, Belgium, Denmark, Spain, United Kingdom, Australia, India, France, Slovakia, Canada, Finland, Germany, Korea, Republic of, Netherlands, Poland
-
Blueprint Medicines CorporationApproved for marketing
-
Arog Pharmaceuticals, Inc.Centre Leon Berard; Fox Chase Cancer CenterUnknownGIST With D842V Mutated PDGFRA GeneUnited States, France, Spain, Italy, Germany, Norway, Poland
-
Chinese University of Hong KongRecruiting
Clinical Trials on Ripretinib
-
Peking UniversityThe First Affiliated Hospital with Nanjing Medical University; Xiangya Hospital... and other collaboratorsActive, not recruitingGastrointestinal Stromal TumorsChina
-
Zai Lab (Shanghai) Co., Ltd.CompletedGastrointestinal Stromal TumorsChina
-
Deciphera Pharmaceuticals LLCCompletedGastrointestinal Stromal Tumors | Advanced Cancers | Advanced Systemic MastocytosisUnited States, Canada, Germany, Italy, Netherlands, United Kingdom
-
Deciphera Pharmaceuticals LLCApproved for marketingGIST - Gastrointestinal Stromal Tumor
-
Deciphera Pharmaceuticals LLCCompletedGastrointestinal Stromal TumorsUnited States, France, Finland, United Kingdom, Germany, Netherlands, Italy, Belgium, Spain, Canada, Australia, Poland, Singapore
-
RenJi HospitalRecruitingGastrointestinal Stromal TumorsChina
-
Deciphera Pharmaceuticals LLCWithdrawnGastrointestinal Stromal Tumors
-
Deciphera Pharmaceuticals LLCActive, not recruitingGIST - Gastrointestinal Stromal TumorUnited States
-
Deciphera Pharmaceuticals LLCPfizerRecruitingColorectal Cancer | GISTUnited States
-
Zai Lab (Shanghai) Co., Ltd.CompletedGastrointestinal Stromal Tumor(GIST)China